Malignant mesothelioma
Clinical trials for Malignant mesothelioma explained in plain language.
Never miss a new study
Get alerted when new Malignant mesothelioma trials appear
Sign up with your email to follow new studies for Malignant mesothelioma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for mesothelioma? drug targets CD30-Positive tumors
Disease control OngoingThis phase 2 trial tests brentuximab vedotin (Adcetris) in 55 patients with CD30+ malignant mesothelioma that cannot be removed by surgery. The drug is an antibody-drug conjugate designed to seek out and attack cancer cells carrying the CD30 marker. The main goal is to see if the…
Matched conditions: MALIGNANT MESOTHELIOMA
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Experimental drug tazemetostat offered to patients with rare, aggressive tumors
Disease control Expanded access (ended)This expanded access program provides tazemetostat, a drug that blocks a protein called EZH2, to adults with serious or life-threatening solid tumors that have lost the INI1 or SMARCA4 protein. Eligible patients must have tried other treatments without success and cannot join a f…
Matched conditions: MALIGNANT MESOTHELIOMA
Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New Dual-Action antibody takes on advanced cancers
Disease control OngoingThis early-phase study tests a new drug called SI-B003 in 60 people with advanced solid tumors that have spread or come back. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to find a safe dose and check for side effect…
Matched conditions: MALIGNANT MESOTHELIOMA
Phase 1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC